WORLD PEPTIDEFOUNDATION
← Master Registry

Non-peptide comparator · published research references

Danuglipron

Governed scientific comparator

4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

This reference comparator is not classified as a peptide.

Approved source records

  1. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.

    DOI: 10.1038/s41591-021-01391-w

    Source identity and connection checked by Codex (AI).

  2. Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.

    DOI: 10.1111/dom.16534

    Source identity and connection checked by Codex (AI).

  3. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.

    DOI: 10.1016/j.metabol.2023.155710

    Source identity and connection checked by Codex (AI).

  4. The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.

    DOI: 10.3389/fendo.2025.1646956

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Karakasis P
  • Patoulias D
  • Pamporis K
  • Stachteas P
  • Bougioukas KI
  • Klisic A
  • Fragakis N
  • Rizzo M
  • Saxena AR
  • Gorman DN
  • Esquejo RM
  • Bergman A
  • Chidsey K
  • Buckeridge C
  • Griffith DA
  • Kim AM
  • Zhou J
  • Wang F
  • Li S
  • Cobain S
  • Bays HE
  • Matsuoka O
  • Fukushima Y
  • Halstead P
  • Tsamandouras N
  • Sherry N